Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance

HER2-targeted therapies for patients with HER2 + breast cancer are rapidly evolving, offering a range of more complex and personalized treatment options. Currently, an array of anti-HER2 monoclonal antibodies, tyrosine kinase inhibitors and antibody–drug conjugates are administered, sometimes alongs...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Nature reviews. Clinical oncology 2024-11, Vol.21 (11), p.818-832
Hauptverfasser:	Waks, Adrienne G., Martínez-Sáez, Olga, Tarantino, Paolo, Braso-Maristany, Fara, Pascual, Tomás, Cortés, Javier, Tolaney, Sara M., Prat, Aleix
Format:	Artikel
Sprache:	eng
Schlagworte:	692/4028/67/1347 692/699/67/1347 Breast cancer Cancer therapies Chemotherapy Endocrine therapy ErbB-2 protein Medicine Medicine & Public Health Monoclonal antibodies Oncology Patients Review Article Trastuzumab Tyrosine kinase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!